{"id":"malathion","rwe":[{"pmid":"41886784","year":"2026","title":"Insecticide Susceptibility of Phlebotomus argentipes and Residual Action of Alpha-Cypermethrin in India: A Multicenter Study.","finding":"","journal":"The American journal of tropical medicine and hygiene","studyType":"Clinical Study"},{"pmid":"41877616","year":"2026","title":"EcCYP89B16 confers metabolic herbicide resistance and is associated with Calvin cycle adjustments in Echinochloa crus-galli.","finding":"","journal":"Plant physiology","studyType":"Clinical Study"},{"pmid":"41863055","year":"2026","title":"Hesperidin-Loaded Chitosan Nanoparticles Restore Hepatic Homeostasis by Targeting Nrf2/HO-1 and NF-κB/p53 Signaling in Malathion-Exposed Rats.","finding":"","journal":"Environmental toxicology","studyType":"Clinical Study"},{"pmid":"41851997","year":"2026","title":"Toxicity of chlorpyrifos, diazinon, malathion, carbaryl and acrolein alone and in mixtures on the fairy shrimp Thamnocephalus platyurus.","finding":"","journal":"Integrated environmental assessment and management","studyType":"Clinical Study"},{"pmid":"41824294","year":"2026","title":"Beyond mortality: biological performance of Trichogramma atopovirilia (Hymenoptera: Trichogrammatidae) exposed to citrus insecticides.","finding":"","journal":"Journal of economic entomology","studyType":"Clinical Study"}],"_fda":{"id":"f0a63cc5-d38b-45b2-8810-f9edcbbde2ce","set_id":"945f46fa-4b79-49fd-a890-477f251e2164","openfda":{"nui":["N0000175723","N0000000177"],"unii":["U5N7SU872W"],"route":["TOPICAL"],"spl_id":["f0a63cc5-d38b-45b2-8810-f9edcbbde2ce"],"brand_name":["Ovide"],"spl_set_id":["945f46fa-4b79-49fd-a890-477f251e2164"],"package_ndc":["51672-5293-4"],"product_ndc":["51672-5293"],"generic_name":["MALATHION"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["MALATHION"],"pharm_class_epc":["Cholinesterase Inhibitor [EPC]"],"pharm_class_moa":["Cholinesterase Inhibitors [MoA]"],"manufacturer_name":["Taro Pharmaceuticals U.S.A., Inc."],"application_number":["ANDA091559"],"is_original_packager":[true]},"version":"2","warnings":["WARNINGS OVIDE Lotion is flammable. The lotion and wet hair should not be exposed to open flames or electric heat sources, including hair dryers and electric curlers. Do not smoke while applying lotion or while hair is wet. Allow hair to dry naturally and to remain uncovered after application of OVIDE Lotion. OVIDE Lotion should only be used on children under the direct supervision of an adult. If OVIDE Lotion comes into contact with the eyes, flush immediately with water. Consult a physician if eye irritation persists. If skin irritation occurs, discontinue use of product until irritation clears. Reapply the OVIDE Lotion, and if irritation reoccurs, consult a physician. Chemical burns including second-degree burns and stinging sensations may occur with the use of OVIDE Lotion. General Keep out of reach of children. Close eyes tightly during product application. If accidentally placed in the eye, flush immediately with water. Use only on scalp hair. Information to Patients OVIDE Lotion is flammable. The lotion and hair wet with lotion should not be exposed to open flames or electric heat sources, including hair dryers and electric curlers. Do not smoke while applying lotion or while hair is wet. The person applying OVIDE Lotion should wash hands after application. Allow hair to dry naturally and to remain uncovered after application of OVIDE Lotion. OVIDE Lotion should only be used on children under the direct supervision of an adult. Children should be warned to stay away from lighted cigarettes, open flames, and electric heat sources while the hair is wet. In case of accidental ingestion of OVIDE Lotion by mouth, seek medical attention immediately. If you are pregnant or nursing, you should contact your physician before using OVIDE Lotion. If OVIDE Lotion comes into contact with the eyes, flush immediately with water. Consult a physician if eye irritation persists or if visual changes occur. If skin irritation occurs, wash scalp and hair immediately. If the irritation clears, OVIDE Lotion may be reapplied. If irritation reoccurs, consult a physician. Burns and stinging sensations may occur when using OVIDE Lotion. Apply OVIDE Lotion on the scalp hair in an amount just sufficient to thoroughly wet hair and scalp. Pay particular attention to the back of the head and neck when applying OVIDE Lotion. Anyone applying OVIDE Lotion should wash hands immediately after the application process is complete. Allow hair to dry naturally and to remain uncovered. Shampoo hair after 8 to 12 hours, again paying attention to the back of the head and neck while shampooing. Rinse hair and use a fine - toothed (nit) comb to remove dead lice and eggs. If lice are still present after 7 - 9 days, repeat with a second application of OVIDE Lotion. Further treatment is generally not necessary. Other family members should be evaluated by a physician to determine if infested, and if so, receive treatment. Laboratory Tests There are no special laboratory tests needed in order to use this medication. Carcinogenesis , Mutagenesis, and Impairment of Fertility Carcinogenesis, mutagenesis and impairment of fertility have not been studied with OVIDE Lotion (0.5% pharmaceutical grade malathion). However, following long-term oral administration of technical grade malathion to rodents via dietary supplementation, increased incidences of hepatocellular neoplastic lesions were observed in B6C3F1 mice dosed for 18 months at malathion doses greater than 1500 mg/kg/day, and in female F344 rats dosed for 2 years at malathion doses greater than 400 mg/kg/day. These tumors occurred only in association with severe hepatic toxicity and chronic suppression of acetylcholinesterase activity, or at doses causing excessive mortality. Based on body surface area, doses at which carcinogenic effects were observed in rodents following life-time exposures to malathion were approximately 14- to 26-fold greater than the maximum dose anticipated in a 10 kg child following a single use of OVIDE Lotion, assuming 100% bioavailability. Actual systemic exposures are expected to be less than 10% of the administered dose. The malathion of greater than pharmaceutical-grade purity used in OVIDE Lotion has not been tested for genotoxicity. The technical-grade malathion (95% pure) was found to be negative in Salmonella typhimurium , equivocally positive in the mouse lymphoma cell assay, and positive in in vitro chromosomal aberration and sister chromatid exchange assays. Fifteen separate in vitro gene mutation studies with malathion of unknown purity have reported negative results, while three studies reported malathion to be mutagenic in bacterial cells. Both technical grade (94–96.5%) and purified (98-99%) malathion have been reported to cause chromosomal aberrations and sister chromatid exchanges in vitro in human and hamster cell lines. In vivo chromosomal aberration and micronucleus studies of technical- grade malathion are reported to be positive, whereas an in vivo chromosomal aberration study of >99% pure malathion was reported to be negative. Furthermore, mice exposed to malathion in their drinking water for 7 weeks demonstrated no evidence of chromosome damage in bone marrow cells, spermatogonia, or primary spermatocytes. Lack of details makes independent evaluation of the results of these assays impossible. Ashby and Purchase have suggested that impurities may be responsible for some of the observed genetic activity of malathion. Reproduction studies performed with malathion in rats at doses over 180 fold greater than those anticipated in a 60 kg adult (based on body surface area and assuming 100% bioavailability) revealed no evidence of impaired fertility. Pregnancy Pregnancy Category B There was no evidence of teratogenicity in studies in rats and rabbits at doses up to 900 mg/kg/day and 100 mg/kg/day malathion, respectively. A study in rats failed to show any gross fetal abnormalities attributable to feeding malathion up to 2,500 ppm (~ 200 mg/kg/day) in the diet during a three - generation evaluation period. These doses were approximately 40 to 180 times higher than the dose anticipated in a 60 kg adult (based on body surface area and assuming 100% bioavailability). Because animal reproduction studies are not always predictive of human responses, this drug should be used (or handled) during pregnancy only if clearly needed. Nursing Mothers Malathion in an acetone vehicle has been reported to be absorbed through human skin to the extent of 8% of the applied dose. However, percutaneous absorption from the OVIDE ® (malathion) Lotion, 0.5% formulation has not been studied, and it is not known whether malathion is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when OVIDE Lotion is administered to (or handled by) a nursing mother. Pediatric Use The safety and effectiveness of OVIDE Lotion in children less than 6 years of age has not been established via well-controlled trials."],"pregnancy":["Pregnancy Pregnancy Category B There was no evidence of teratogenicity in studies in rats and rabbits at doses up to 900 mg/kg/day and 100 mg/kg/day malathion, respectively. A study in rats failed to show any gross fetal abnormalities attributable to feeding malathion up to 2,500 ppm (~ 200 mg/kg/day) in the diet during a three - generation evaluation period. These doses were approximately 40 to 180 times higher than the dose anticipated in a 60 kg adult (based on body surface area and assuming 100% bioavailability). Because animal reproduction studies are not always predictive of human responses, this drug should be used (or handled) during pregnancy only if clearly needed."],"overdosage":["OVERDOSAGE Consideration should be given, as part of the treatment program, to the high concentration of isopropyl alcohol in the vehicle. Malathion, although a weaker cholinesterase inhibitor than some other organophosphates, may be expected to exhibit the same symptoms of cholinesterase depletion after accidental ingestion orally. If accidentally swallowed, vomiting should be induced promptly or the stomach lavaged with 5% sodium bicarbonate solution. Severe respiratory distress is the major and most serious symptom of organophosphate poisoning requiring artificial respiration, and atropine may be needed to counteract the symptoms of cholinesterase depletion. Repeat analyses of serum and RBC cholinesterase may assist in establishing the diagnosis and formulating a long - range prognosis."],"description":["DESCRIPTION OVIDE Lotion contains 0.005 g of malathion per mL in a vehicle of isopropyl alcohol (78%), terpineol, dipentene, and pine needle oil. The chemical name of malathion is (±) - [(dimethoxyphosphinothioyl) - thio] butanedioic acid diethyl ester. Malathion has a molecular weight of 330.36, represented by C 10 H 19 O 6 PS 2 , and has the following chemical structure: Chemical Structure"],"how_supplied":["HOW SUPPLIED OVIDE ® (malathion) Lotion, 0.5%, is supplied in bottles of 2 fl. oz. (59 mL) NDC 51672-5293-4. Stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature] Flammable. Keep away from heat and open flame."],"pediatric_use":["Pediatric Use The safety and effectiveness of OVIDE Lotion in children less than 6 years of age has not been established via well-controlled trials."],"effective_time":"20180720","nursing_mothers":["Nursing Mothers Malathion in an acetone vehicle has been reported to be absorbed through human skin to the extent of 8% of the applied dose. However, percutaneous absorption from the OVIDE ® (malathion) Lotion, 0.5% formulation has not been studied, and it is not known whether malathion is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when OVIDE Lotion is administered to (or handled by) a nursing mother."],"clinical_studies":["Clinical Studies Two controlled clinical trials evaluated the pediculicidal activity of OVIDE Lotion. Patients applied the lotion to the hair and scalp in quantities, up to a maximum of 2 fl. oz., sufficient to thoroughly wet the hair and scalp. The lotion was allowed to air dry and was shampooed with Prell shampoo 8 to 12 hours after application. Patients in both the OVIDE Lotion group and in the vehicle group were examined immediately after shampooing, 24 hours after, and 7 days after for the presence of live lice. Results are shown in the following table: Number of Patients without Live Scalp Lice Treatment Immediately After 24 Hrs. After 7 Days After OVIDE Lotion 129/129 122/129 114/126 OVIDE Vehicle 105/105 63/105 31/105 The presence or absence of ova at day 7 was not evaluated in these studies. The presence or absence of live lice or ova at 14 days following treatment was not evaluated in these studies. The residual amount of malathion on hair and scalp is unknown."],"laboratory_tests":["Laboratory Tests There are no special laboratory tests needed in order to use this medication."],"adverse_reactions":["ADVERSE REACTIONS Malathion has been shown to be irritating to the skin and scalp. Other adverse reactions reported are chemical burns including second-degree burns. Accidental contact with the eyes can result in mild conjunctivitis. It is not known if OVIDE Lotion has the potential to cause contact allergic sensitization."],"contraindications":["CONTRAINDICATIONS OVIDE Lotion is contraindicated for neonates and infants because their scalps are more permeable and may have increased absorption of malathion. OVIDE Lotion should also not be used on individuals known to be sensitive to malathion or any of the ingredients in the vehicle."],"general_precautions":["General Keep out of reach of children. Close eyes tightly during product application. If accidentally placed in the eye, flush immediately with water. Use only on scalp hair."],"teratogenic_effects":["Pregnancy Category B There was no evidence of teratogenicity in studies in rats and rabbits at doses up to 900 mg/kg/day and 100 mg/kg/day malathion, respectively. A study in rats failed to show any gross fetal abnormalities attributable to feeding malathion up to 2,500 ppm (~ 200 mg/kg/day) in the diet during a three - generation evaluation period. These doses were approximately 40 to 180 times higher than the dose anticipated in a 60 kg adult (based on body surface area and assuming 100% bioavailability). Because animal reproduction studies are not always predictive of human responses, this drug should be used (or handled) during pregnancy only if clearly needed."],"storage_and_handling":["Stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature] Flammable. Keep away from heat and open flame."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Malathion is an organophosphate agent which acts as a pediculicide by inhibiting cholinesterase activity in vivo. Inadvertent transdermal absorption of malathion has occurred from its agricultural use. In such cases, acute toxicity was manifested by excessive cholinergic activity, i.e., increased sweating, salivary and gastric secretion, gastrointestinal and uterine motility, and bradycardia (see OVERDOSAGE ). Because the potential for transdermal absorption of malathion from OVIDE Lotion is not known at this time, strict adherence to the dosing instructions regarding its use in children, method of application, duration of exposure, and frequency of application is required."],"indications_and_usage":["INDICATIONS AND USAGE OVIDE Lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair."],"clinical_studies_table":["<table width=\"75%\"> <caption>Number of Patients without Live Scalp Lice</caption> <col width=\"25%\" align=\"center\" valign=\"middle\"/> <col width=\"25%\" align=\"center\" valign=\"middle\"/> <col width=\"25%\" align=\"center\" valign=\"middle\"/> <col width=\"25%\" align=\"center\" valign=\"middle\"/> <thead> <tr> <th styleCode=\"Lrule Rrule\">Treatment</th> <th styleCode=\"Rrule\">Immediately After</th> <th styleCode=\"Rrule\">24 Hrs. After</th> <th styleCode=\"Rrule\">7 Days After</th> </tr> </thead> <tbody> <tr styleCode=\"Botrule\"> <td styleCode=\"Lrule Rrule\">OVIDE Lotion</td> <td styleCode=\"Rrule\">129/129</td> <td styleCode=\"Rrule\">122/129</td> <td styleCode=\"Rrule\">114/126</td> </tr> <tr> <td styleCode=\"Lrule Rrule\">OVIDE Vehicle</td> <td styleCode=\"Rrule\">105/105</td> <td styleCode=\"Rrule\">63/105</td> <td styleCode=\"Rrule\">31/105</td> </tr> </tbody> </table>"],"information_for_patients":["Information to Patients OVIDE Lotion is flammable. The lotion and hair wet with lotion should not be exposed to open flames or electric heat sources, including hair dryers and electric curlers. Do not smoke while applying lotion or while hair is wet. The person applying OVIDE Lotion should wash hands after application. Allow hair to dry naturally and to remain uncovered after application of OVIDE Lotion. OVIDE Lotion should only be used on children under the direct supervision of an adult. Children should be warned to stay away from lighted cigarettes, open flames, and electric heat sources while the hair is wet. In case of accidental ingestion of OVIDE Lotion by mouth, seek medical attention immediately. If you are pregnant or nursing, you should contact your physician before using OVIDE Lotion. If OVIDE Lotion comes into contact with the eyes, flush immediately with water. Consult a physician if eye irritation persists or if visual changes occur. If skin irritation occurs, wash scalp and hair immediately. If the irritation clears, OVIDE Lotion may be reapplied. If irritation reoccurs, consult a physician. Burns and stinging sensations may occur when using OVIDE Lotion. Apply OVIDE Lotion on the scalp hair in an amount just sufficient to thoroughly wet hair and scalp. Pay particular attention to the back of the head and neck when applying OVIDE Lotion. Anyone applying OVIDE Lotion should wash hands immediately after the application process is complete. Allow hair to dry naturally and to remain uncovered. Shampoo hair after 8 to 12 hours, again paying attention to the back of the head and neck while shampooing. Rinse hair and use a fine - toothed (nit) comb to remove dead lice and eggs. If lice are still present after 7 - 9 days, repeat with a second application of OVIDE Lotion. Further treatment is generally not necessary. Other family members should be evaluated by a physician to determine if infested, and if so, receive treatment."],"spl_unclassified_section":["NDC 51672-5293-4 Rx Only For topical use only. Not for oral or ophthalmic use.","Manufactured for: TaroPharma ® a division of Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532 Manufactured By: Suven Life Sciences Limited, Plot No. 262-271, IDA, Pashamylaram, Sangareddy District, Telangana, 502307 India. Ovide ® and TaroPharma ® are trademarks of Taro Pharmaceuticals U.S.A., Inc. and/or its affiliates. Lb30005-4-02 Issued: March, 2017 0317-2"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Apply OVIDE Lotion on DRY hair in amount just sufficient to thoroughly wet the hair and scalp. Pay particular attention to the back of the head and neck while applying OVIDE Lotion. Wash hands after applying to scalp. Allow hair to dry naturally - use no electric heat source, and allow hair to remain uncovered. After 8 to 12 hours, the hair should be shampooed. Rinse and use a fine - toothed (nit) comb to remove dead lice and eggs. If lice are still present after 7 - 9 days, repeat with a second application of OVIDE Lotion. Further treatment is generally not necessary. Other family members should be evaluated by a physician to determine if infested, and if so, receive treatment."],"spl_product_data_elements":["Ovide Malathion Malathion Malathion isopropyl alcohol terpineol limonene, (+/-)- pine needle oil (pinus sylvestris)"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 59 mL Bottle Carton NDC 51672-5293-4 OVIDE ® (malathion) LOTION, 0.5% In isopropyl alcohol (78%), terpineol, dipentene and pine needle oil. PEDICULICIDE/OVICIDE WARNING: Contains flammable alcohol. Avoid smoking, open flame and hair dryers. Allow hair to dry naturally and uncovered. Rx Only Taro Pharma ® 2 fl. oz. (59 mL) PRINCIPAL DISPLAY PANEL - 59 mL Bottle Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis , Mutagenesis, and Impairment of Fertility Carcinogenesis, mutagenesis and impairment of fertility have not been studied with OVIDE Lotion (0.5% pharmaceutical grade malathion). However, following long-term oral administration of technical grade malathion to rodents via dietary supplementation, increased incidences of hepatocellular neoplastic lesions were observed in B6C3F1 mice dosed for 18 months at malathion doses greater than 1500 mg/kg/day, and in female F344 rats dosed for 2 years at malathion doses greater than 400 mg/kg/day. These tumors occurred only in association with severe hepatic toxicity and chronic suppression of acetylcholinesterase activity, or at doses causing excessive mortality. Based on body surface area, doses at which carcinogenic effects were observed in rodents following life-time exposures to malathion were approximately 14- to 26-fold greater than the maximum dose anticipated in a 10 kg child following a single use of OVIDE Lotion, assuming 100% bioavailability. Actual systemic exposures are expected to be less than 10% of the administered dose. The malathion of greater than pharmaceutical-grade purity used in OVIDE Lotion has not been tested for genotoxicity. The technical-grade malathion (95% pure) was found to be negative in Salmonella typhimurium , equivocally positive in the mouse lymphoma cell assay, and positive in in vitro chromosomal aberration and sister chromatid exchange assays. Fifteen separate in vitro gene mutation studies with malathion of unknown purity have reported negative results, while three studies reported malathion to be mutagenic in bacterial cells. Both technical grade (94–96.5%) and purified (98-99%) malathion have been reported to cause chromosomal aberrations and sister chromatid exchanges in vitro in human and hamster cell lines. In vivo chromosomal aberration and micronucleus studies of technical- grade malathion are reported to be positive, whereas an in vivo chromosomal aberration study of >99% pure malathion was reported to be negative. Furthermore, mice exposed to malathion in their drinking water for 7 weeks demonstrated no evidence of chromosome damage in bone marrow cells, spermatogonia, or primary spermatocytes. Lack of details makes independent evaluation of the results of these assays impossible. Ashby and Purchase have suggested that impurities may be responsible for some of the observed genetic activity of malathion. Reproduction studies performed with malathion in rats at doses over 180 fold greater than those anticipated in a 60 kg adult (based on body surface area and assuming 100% bioavailability) revealed no evidence of impaired fertility."]},"tags":[{"label":"Cholinesterase Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Melatonin receptor type 1A","category":"target"},{"label":"MTNR1A","category":"gene"},{"label":"P03AX03","category":"atc"},{"label":"Topical","category":"route"},{"label":"Lotion","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Pediculosis capitis","category":"indication"},{"label":"Taro","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Cholinergic Agents","category":"pharmacology"},{"label":"Cholinesterase Inhibitors","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Insecticides","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Pesticides","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"12 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"11 reports"},{"date":"","signal":"ALOPECIA","source":"FDA FAERS","actionTaken":"9 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"8 reports"},{"date":"","signal":"DRUG EXPOSURE DURING PREGNANCY","source":"FDA FAERS","actionTaken":"7 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"7 reports"},{"date":"","signal":"PREGNANCY WITH INJECTABLE CONTRACEPTIVE","source":"FDA FAERS","actionTaken":"7 reports"},{"date":"","signal":"THERMAL BURN","source":"FDA FAERS","actionTaken":"7 reports"},{"date":"","signal":"BURNS SECOND DEGREE","source":"FDA FAERS","actionTaken":"5 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"5 reports"}],"commonSideEffects":[{"effect":"second-degree burns","drugRate":"reported","severity":"unknown"},{"effect":"chemical burns","drugRate":"reported","severity":"unknown"},{"effect":"mild conjunctivitis","drugRate":"reported","severity":"unknown"},{"effect":"contact allergic sensitization","drugRate":"reported","severity":"unknown"},{"effect":"skin irritation","drugRate":"reported","severity":"unknown"},{"effect":"scalp irritation","drugRate":"reported","severity":"unknown"}],"contraindications":["Skin irritation"],"specialPopulations":{"Pregnancy":"Pregnancy Category B. There was no evidence of teratogenicity in studies in rats and rabbits at doses up to 900 mg/kg/day and 100 mg/kg/day malathion, respectively. study in rats failed to show any gross fetal abnormalities attributable to feeding malathion up to 2,500 ppm (~ 200 mg/kg/day) in the diet during three generation evaluation period. These doses were approximately 40 to 180 times higher than the dose anticipated in 60 kg adult (based on body surface area and assuming 100% bioavailability).","Paediatric use":"The safety and effectiveness of malathion lotion in children less than 12 years of age has not been established via well-controlled trials."}},"trials":[],"aliases":[],"company":"Taro","patents":[{"applNo":"N018613","source":"FDA Orange Book","status":"Active","expires":"Feb 1, 2027","useCode":"U-986","territory":"US","drugProduct":true,"patentNumber":"7560445","drugSubstance":true},{"applNo":"N018613","source":"FDA Orange Book","status":"Active","expires":"Aug 14, 2026","useCode":"","territory":"US","drugProduct":true,"patentNumber":"7977324","drugSubstance":false}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$3.2612/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$1,174","description":"MALATHION 0.5% LOTION","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MALATHION","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:15:40.420446+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:15:40.420097+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:15:47.096719+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:15:39.012271+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MALATHION","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:15:47.928349+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:15:38.139860+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:15:38.139917+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:15:38.139935+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:15:49.432181+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Acetylcholinesterase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:15:48.513231+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200468/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:15:48.409488+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA091559","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:15:38.139944+00:00"}},"allNames":"ovide","offLabel":[],"synonyms":["malathion","carbetovur","carbetox","carbofos","carbophos","cimexan","ethiolacar","malathine","malathyne","sadofos"],"timeline":[{"date":"1982-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from TARO PHARMS NORTH to Taro"},{"date":"1982-08-02","type":"positive","source":"DrugCentral","milestone":"FDA approval (Taro Pharms North)"},{"date":"2009-03-06","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"},{"date":"2027-02-01","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 7560445 expires"}],"aiSummary":"Ovide (MALATHION) is a cholinesterase inhibitor small molecule developed by TARO PHARMS NORTH and currently owned by Taro. It targets the melatonin receptor type 1A and is approved by the FDA for the treatment of pediculosis capitis since 1982. As an off-patent medication, Ovide is available as a generic from multiple manufacturers. Key safety considerations include its potential toxicity and environmental concerns. Commercially, Ovide is available as a generic medication.","approvals":[{"date":"1982-08-02","orphan":false,"company":"TARO PHARMS NORTH","regulator":"FDA"}],"brandName":"Ovide","ecosystem":[{"indication":"Pediculosis capitis","otherDrugs":[{"name":"abametapir","slug":"abametapir","company":"Dr Reddys Labs Sa"},{"name":"lidocaine","slug":"lidocaine","company":"Fresenius Kabi Usa"},{"name":"lindane","slug":"lindane","company":"Reed And Carnrick"},{"name":"permethrin","slug":"permethrin","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Melatonin receptor type 1A","novelty":"Follow-on","targets":[{"gene":"MTNR1A","source":"DrugCentral","target":"Melatonin receptor type 1A","protein":"Melatonin receptor type 1A"}],"moaClass":"Cholinesterase Inhibitors","modality":"Small Molecule","drugClass":"Cholinesterase Inhibitor [EPC]","explanation":"","oneSentence":"","technicalDetail":"Ovide (MALATHION) acts as a cholinesterase inhibitor by binding to the active site of acetylcholinesterase, thereby preventing the breakdown of acetylcholine and leading to an accumulation of this neurotransmitter in the nervous system of the target organism, ultimately resulting in its death."},"commercial":{"launchDate":"1982","_launchSource":"DrugCentral (FDA 1982-08-02, TARO PHARMS NORTH)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1626","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MALATHION","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MALATHION","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:29:45.782742","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:15:52.853227+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"benzyl benzoate","drugSlug":"benzyl-benzoate","fdaApproval":"1976-09-02","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"dimethicone","drugSlug":"dimethicone","fdaApproval":"1997-06-26","relationship":"same-class"},{"drugName":"benzyl alcohol","drugSlug":"benzyl-alcohol","fdaApproval":"2009-04-09","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"abametapir","drugSlug":"abametapir","fdaApproval":"2020-07-24","patentExpiry":"Oct 28, 2026","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"malathion","indications":{"approved":[{"name":"Pediculosis capitis","source":"DrugCentral","snomedId":81000006,"regulator":"FDA","eligibility":"patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair"}],"offLabel":[],"pipeline":[]},"currentOwner":"Taro","drugCategory":"mature","labelChanges":[],"relatedDrugs":[{"drugId":"benzyl-benzoate","brandName":"benzyl benzoate","genericName":"benzyl benzoate","approvalYear":"1976","relationship":"same-class"},{"drugId":"dimethicone","brandName":"dimethicone","genericName":"dimethicone","approvalYear":"1997","relationship":"same-class"},{"drugId":"benzyl-alcohol","brandName":"benzyl alcohol","genericName":"benzyl alcohol","approvalYear":"2009","relationship":"same-class"},{"drugId":"abametapir","brandName":"abametapir","genericName":"abametapir","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03236168","phase":"PHASE3","title":"Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2017-08-01","conditions":["Scabies","Head Lice"],"enrollment":118,"completionDate":"2018-02-28"},{"nctId":"NCT02213055","phase":"PHASE2","title":"Pediatric Head Lice Study Product Comparison","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2009-05","conditions":["Head Lice"],"enrollment":97,"completionDate":"2014-08"},{"nctId":"NCT00752973","phase":"PHASE2,PHASE3","title":"Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2008-09","conditions":["Pediculosis"],"enrollment":12,"completionDate":"2012-01"},{"nctId":"NCT00927472","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2009-08","conditions":["Pediculosis"],"enrollment":254,"completionDate":"2010-06"},{"nctId":"NCT00963508","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2009-08","conditions":["Pediculosis"],"enrollment":403,"completionDate":"2010-03"},{"nctId":"NCT00927407","phase":"PHASE1","title":"Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2009-07","conditions":["Pediculosis"],"enrollment":24,"completionDate":"2009-08"},{"nctId":"NCT00244439","phase":"PHASE3","title":"Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2005-12","conditions":["Lice Infestations"],"enrollment":360,"completionDate":"2006-12"},{"nctId":"NCT00291057","phase":"PHASE2","title":"Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice","status":"TERMINATED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2006-02","conditions":["Lice Infestations"],"enrollment":30,"completionDate":"2006-12"},{"nctId":"NCT00819520","phase":"PHASE3","title":"Ivermectin in the Treatment of Head Lice","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer and Personal Products Worldwide","startDate":"2004-02","conditions":["Lice Infestations"],"enrollment":812,"completionDate":"2004-10"},{"nctId":"NCT00758823","phase":"NA","title":"Randomized Controlled Trial Comparing Efficacy and Tolerance of Four Pediculicides","status":"COMPLETED","sponsor":"Omega Pharma","startDate":"2008-08","conditions":["Headlice Infections"],"enrollment":750,"completionDate":"2008-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical","formulation":"Lotion","formulations":[{"form":"LOTION","route":"TOPICAL","productName":"Malathion"},{"form":"LOTION","route":"TOPICAL","productName":"Ovide"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146761","MMSL":"165167","NDDF":"002995","UNII":"U5N7SU872W","VUID":"4018435","CHEBI":"CHEBI:6651","VANDF":"4018435","RXNORM":"6606","UMLSCUI":"C0024547","chemblId":"CHEMBL1200468","ChEMBL_ID":"CHEMBL1200468","KEGG_DRUG":"D00534","DRUGBANK_ID":"DB00772","PUBCHEM_CID":"4004","SNOMEDCT_US":"333071000","MESH_DESCRIPTOR_UI":"D008294"},"formularyStatus":[],"originalProduct":{"form":"LOTION","route":"TOPICAL","company":"Taro Pharmaceuticals U.S.A., Inc.","brandName":"Ovide","isOriginal":true,"marketingStatus":"ANDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1982-","companyName":"Taro Pharms North","relationship":"Original Developer"},{"period":"present","companyName":"Taro","relationship":"Current Owner"}],"publicationCount":4326,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"P03AX03","allCodes":["P03AX03"]},"biosimilarFilings":[],"originalDeveloper":"Taro Pharms North","recentPublications":[{"date":"2026 Mar 26","pmid":"41886784","title":"Insecticide Susceptibility of Phlebotomus argentipes and Residual Action of Alpha-Cypermethrin in India: A Multicenter Study.","journal":"The American journal of tropical medicine and hygiene"},{"date":"2026 Mar 24","pmid":"41877616","title":"EcCYP89B16 confers metabolic herbicide resistance and is associated with Calvin cycle adjustments in Echinochloa crus-galli.","journal":"Plant physiology"},{"date":"2026 Mar 20","pmid":"41863055","title":"Hesperidin-Loaded Chitosan Nanoparticles Restore Hepatic Homeostasis by Targeting Nrf2/HO-1 and NF-κB/p53 Signaling in Malathion-Exposed Rats.","journal":"Environmental toxicology"},{"date":"2026 Mar 18","pmid":"41851997","title":"Toxicity of chlorpyrifos, diazinon, malathion, carbaryl and acrolein alone and in mixtures on the fairy shrimp Thamnocephalus platyurus.","journal":"Integrated environmental assessment and management"},{"date":"2026 Mar 13","pmid":"41824294","title":"Beyond mortality: biological performance of Trichogramma atopovirilia (Hymenoptera: Trichogrammatidae) exposed to citrus insecticides.","journal":"Journal of economic entomology"}],"companionDiagnostics":[],"genericManufacturers":2,"_genericFilersChecked":true,"genericManufacturerList":["Pharmobedient","Suven Pharms"],"status":"approved","companyName":"Taro","companyId":"taro","modality":"Small molecule","firstApprovalDate":"1982","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1982-08-02T00:00:00.000Z","mah":"TARO PHARMS NORTH","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-05-23T00:00:00.000Z","mah":"SUVEN PHARMS","brand_name_local":null,"application_number":"ANDA091559"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:15:52.853227+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}